Abstracts tagged "Health Services Research"

Abstract Number: 0806 • ACR Convergence 2023
Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Linda Li¹, Hui Xie², Lynne feehan¹, Na Lu³, Alison Hoens⁴, Kelly English⁵, Eileen Davidson⁵, Catherine L. Backman⁶, Smruthi Ramachandran¹, Ellen Wang¹, Stephanie Therrien³, Julia Mucha¹, Teresa Liu-Ambrose¹, Kimberly Miller⁷, Christopher Shaw⁸ and Diane Lacaille⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board, Arthritis Research Canada, Vancouver, BC, Canada, ⁶The University of British Columbia, Vancouver, BC, Canada, ⁷BC Children’s and Women’s Hospital & Health Centre, Vancouver, BC, Canada, ⁸Simon Fraser University, Burnaby, BC, Canada, ⁹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: To achieve optimal health outcomes, people with rheumatoid arthritis (RA) need to know their symptom patterns and be able to practice self-care activities. With…
Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Joshua Skydel¹, Reshma Ramachandran², Sakinah Suttiratana², Joseph Ross², Joshua Wallach³ and Christopher Burns⁴, ¹Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Yale University, New Haven, CT, ³Emory University, Atlanta, GA, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…
Abstract Number: 1858 • ACR Convergence 2023
How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors?
Nick Bansback¹, Michael law¹, Fiona Clemont², Mina Tadrous³, Sandra Blitz¹ and Mark Harrison¹, ¹University of British Columbia, Vancouver, BC, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: In response to the low uptake of biosimilars, British Columbia (BC) in Canada became the first jurisdiction in North America to require patients with…
Abstract Number: 0169 • ACR Convergence 2023
Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Alejandro Figueroa-Lara¹, Mary Ann Aure² and Carmen Andalucia¹, ¹Werfen, San Diego, CA, ²Werfen, Chula Vista, CA
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…
Abstract Number: 0808 • ACR Convergence 2023
Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System
Bryant England¹, Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Daniel Hershberger¹, Brian Sauer², Grant Cannon³, Joshua Baker⁴ and Ted R Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There are currently no clinical practice guidelines for monitoring RA-associated interstitial lung disease (RA-ILD). Pulmonary function tests (PFTs) and chest computed tomography (CT) imaging…
Abstract Number: 1617 • ACR Convergence 2023
Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022
Eric Roberts¹, Jing Li¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski¹, Gabriela Schmajuk⁴ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, HI, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: The first infliximab biosimilar (infliximab-dybb) entered the U.S. market in 2016, and two additional products have subsequently been introduced (infliximab-axxq (2017) and infliximab-abda (2020)).…
Abstract Number: 1860 • ACR Convergence 2023
Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis
Alyssa Howren¹, Eric Sayre², J. Antonio Avina-Zubieta³, Joseph Puyat¹, Deborah Da Costa⁴, Hui Xie⁵, Amit Gupta¹ and Mary De Vera¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Simon Fraser University, Richmond, BC, Canada
Background/Purpose: To describe patterns of pharmacological and psychological treatment and evaluate the receipt of minimally adequate treatment for incident depression and anxiety in individuals with…
Abstract Number: 0170 • ACR Convergence 2023
Gender Equity Amongst Rheumatology Professionals: Preliminary Findings of the Coalition for Health and Gender Equity E-survey (CHANGE Group)
Lisa Traboco¹, Pavel Ovseiko², Sarah Dyball³, Tayyeba Khursheed⁴, ALEJANDRA BABINI⁵, Asgar Ali Kalla⁶, Catherine Hill⁷, Debashish Danda⁸, Dzifa Dey⁹, Elena Nikiphorou¹⁰, Ghita Harifi¹¹, Ho SO¹², Humeira Badshah¹³, Ihsane Hmamouchi¹⁴, Joan Marie Von Feldt¹⁵, Júlia Boechat Farani¹⁶, Mariana Peixoto Guimarães¹⁷, Kanon Jatuworapruk¹⁸, Laura Andreoli¹⁹, Nelly Ziade²⁰, PENELOPE PALOMINOS²¹, Qian Wang²², Ran Nakashima²³, Syed Haq²⁴, Wilson Bautista-Molano²⁵, Yoshiya Tanaka²⁶, Grace Wright²⁷, Vikas Agarwal²⁸, Laura Coates²⁹ and Latika Gupta³⁰, ¹University of the Philippines - Manila, St Luke's Medical Center - Bonifacio Global City, Paranaque, Manila, Philippines, ²Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom, ³University of Manchester, Stockport, United Kingdom, ⁴Pakistan institute of Medical Sciences, Islamabad, Pakistan, ⁵Hospital Italiano Cordoba, Cordoba, Argentina, ⁶Department of Medicine, University of Cape Town, Cape Town, South Africa, ⁷The Queen Elizabeth Hospital, Woodville, Australia, ⁸Christian Medical College & Hospital, Vellore, India, ⁹University of Ghana Medical School, Rheumatology Unit Department of Medicine and Therapeutics, Korle bu Teaching Hospital, Accra, Ghana, ¹⁰King's College London, London, United Kingdom, ¹¹HBMC, Dubai, United Arab Emirates, ¹²The Chinese University of Hong Kong, Hong Kong, China, ¹³Dr Humeira Badsha Medical Center, Dubai, United Arab Emirates, Dubai, United Arab Emirates, ¹⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Morocco, ¹⁵University of Pennsylvania, Pennsylvania, PA, ¹⁶Division of Rheumatology, Hospital Santa Casa de Misericórdia de Juiz de Fora, Juiz de Fora, Brazil, ¹⁷Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, MG, Brazil, ¹⁸Thammasat University, Pathumthani, Thailand, ¹⁹University of Brescia, Brescia, Italy, ²⁰Saint-Joseph University, Beirut, Lebanon, ²¹Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ²²Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China, ²³Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²⁴BSM Medical University, Dhaka, Bangladesh, ²⁵University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁷Grace C Wright MD PC, New York, NY, ²⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²⁹University of Oxford, Oxford, United Kingdom, ³⁰Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: There is growing attention to gender inequity within rheumatology with persistent challenges in achieving pay parity, career progression, & access to leadership roles. In…
Abstract Number: 0996 • ACR Convergence 2023
Will Patients Engage with Digital Technologies as Part of Routine Healthcare?
Jeffrey R Curtis¹, Sandeep Sodhi², Yuji Su³, Scott Laster⁴, Fenglong Xie², Ye Liu⁵ and Corey Patrick⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Illumination Health, Hoover, AL, ³University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ⁴Micare, Memphis, TN, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) are new care delivery options by which patients can provide data to their provider via…
Abstract Number: 1618 • ACR Convergence 2023
Intervention to Improve Medication Adherence Among Patients with SLE
Kai Sun¹, Nneka Molokwu¹, Emily Hanlen¹, Amy Corneli², Kathryn Pollak¹, Jennifer Rogers¹, Rebecca Sadun¹, Lisa Criscione-Schreiber², Jayanth Doss¹, Hayden Bosworth¹ and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is common and is associated with increased disease activity, morbidity, and mortality in SLE. To optimize medication adherence and SLE outcomes, we…
Abstract Number: 1908 • ACR Convergence 2023
Clinic Protocol Boosts Blood Pressure Confirmatory Readings and Accuracy in an Academic Medical Center
Kubra Bugdayli¹, Amber Meyer¹, Antoinette Keith¹, Karunakar Dirisala¹, Guillermo Quiceno¹ and Puneet Bajaj², ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hypertension is the most common modifiable risk factor for cardiovascular diseases among all adults. Studies have shown that single blood pressure (BP) measurements vary…
Abstract Number: 0171 • ACR Convergence 2023
A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews
Vibeke Strand¹, Prajakta Masurkar², Jennifer Reckleff³, Taylor Schwartz⁴, Alison Silverstein⁴, Jennifer Osborne⁴, Josie Lloyd⁴, Brian Leinwand⁴, Elaine Karis⁵, Fatima Barbar-Smiley⁶ and Karen Costenbader⁷, ¹Stanford University, Portola Valley, CA, ²Amgen, Inc., Atlanta, GA, ³Amgen, Inc., Westlake Village, CA, ⁴Inovalon Insights, Bowie, MD, ⁵Amgen, Inc., Colts Neck, NJ, ⁶Amgen, Inc., Dublin, OH, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes,…
Abstract Number: 0997 • ACR Convergence 2023
Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus
W. Cliff Rutter, Jean Park, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) have higher rates of psychiatric comorbidities, particularly depression and anxiety. Comorbid…
Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Carolyn Thorpe, Ryan Hickson, Sherrie Aspinall, Vimal Derebail, Xinhua Zhao, Joshua Thorpe, Binxin Cao, Alexa Ehlert, Ronald Falk and Susan Hogan, University of North Carolina, Chapel Hill, NC
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…
Abstract Number: 2002 • ACR Convergence 2023
Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Yamei Wang⁴, Leny Pearman⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Boston, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…

« Previous Page
1
…
5
6
7
8
9
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].